Major increase in EU's contribution to Global Fund

3 March 2016

March 4, 2016

The European Union Commissioner for International Cooperation and Development, Neven Mimica, today announced the EU's contribution of 470 million euros ($509 million) to the Global Fund to Fight AIDS, Tuberculosis and Malaria for the period 2017-2019.

The new funding represents an increase of 100 million euros or 27% of the EU's contribution in comparison to previous years (370 million euros for 2014-2016). This grant supports the Global Fund's objective to help save 8 million lives over the next three years and reach the SDG target of ending the epidemics of HIV, Tuberculosis and Malaria by 2030.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK